USPSFT provides draft recommendations for aspirin therapy in primary CVD prevention; FDA warns against use of needle-free devices for dermal fillers; REMS modifications for isotretinoin products; new treatment for pediatric congenital athymia; Emergency Authorization Use request submitted for an oral COVID-19 treatment; an FDA advisory panel votes on the Moderna COVID-19 vaccine booster.